Research programme: Ophthalmic disease therapeutics - Iconic therapeutics
Latest Information Update: 30 Nov 2023
At a glance
- Originator Iconic Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 19 Oct 2023 Preclinical trials in Eye disorders in USA (Parenteral)